CellGF BioMed is a nucleotide technology development company, specializing in the research on DNA and RNA. The global sales of nucleotide related products are over ten billion US dollars. Because there are only several manufacturers of nucleotides and the high cost of nucleotide materials, we have developed the leading nucleotide process technology. The nucleotide application are very important in the molecular detection and pharmaceutical industry.

The technological innovation of CellGF BioMed is using special enzymes to produce nucleotides in biological reaction. Our patented nucleotide biological process technology has three advantages: low cost, stable supply, and non-toxic. Our nucleotides could be used as research reagents for molecular detection and raw materials for skin care products, health products, medical products and medicines. The unique technology of CellGF BioMed has gained many entrepreneurship competition awards and prizes from National Tsing Hua University and Ministry of Science and Technology. In year 2018, CellGF BioMed was approved stationed in R&D center of Hsinchu Science Park.

With the development of biotechnology, more and more companies are developing nucleotide based drugs in the world, the importance of nucleotide raw materials is also increasing. In recent years, it has been proven that nucleotide-based drugs can break through the problem of genetic diseases, autoimmune diseases, cancer and viral infections that cannot be solved by small molecule drug or protein drug. CellGF BioMed is recently building an RNA drug production platform with special modified nucleotides. At present, there is lack of professional commissioned production services for RNA medicines in the world. In the future, CellGF BioMed will assist domestic and foreign academic research institutes and new drug companies to produce RNA medicines through customized commissioning services. CellGF BioMed hope to be the leading team to develop new nucleotide application products.